Every open market buy and sale of Monte Rosa Therapeutics, Inc. stock by its officers, directors and 10% owners over the last two years, straight from SEC Form 4 filings. Insiders are only selling over the last 12 months: $0 bought and $4.1M sold.
Buying and selling by month
open market, last 12 monthsGet an alert when GLUE insiders trade
We read every Form 4 the moment the SEC posts it and tell you when an GLUE officer, director or 10% owner buys on the open market, or sells $250K or more outside a pre-arranged plan, by email or on your phone.
Insider alerts are part of AI Pro. Start with a free account, then add AI Pro when you want the alerts.
Every GLUE insider trade
2 years · newest first| Insider | Type | Price | Held after | Filed | |||
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | Matthew BowenPrincipal Accounting Officer | Sale | 13 | $10.56 | $137 | 25,891 | Oct 6Form 4 |
| Jul 16, 2026 | Markus WarmuthPresident & CEO | Sale | 9,500 | $23.18 | $220K | 585,038 | Jul 17Form 4 |
| Jul 15, 2026 | Jennifer ChampouxCOO | Sale plan | 4,351 | $23.38 | $102K | 62,371 | Jul 16Form 4 |
| Jul 6, 2026 | Sharon TownsonChief Scientific Officer | Sale plan | 6,000 | $23.31 | $140K | 67,845 | Jul 7Form 4 |
| Jun 30, 2026 | Filip JankuChief Medical Officer | Sale plan | 5,407 | $24.50 | $132K | 60,612 | Jul 1Form 4 |
| Jun 29, 2026 | Anthony M. ManningDirector | Sale | 10,000 | $23.11 | $231K | 0 | Jun 30Form 4 |
| Jun 29, 2026 | Filip JankuChief Medical Officer | Sale plan | 6,000 | $22.95 | $138K | 59,992 | Jun 30Form 4 |
| Jun 24, 2026 | Filip JankuChief Medical Officer | Sale plan | 41,845 | $21.08 | $882K | 59,992 | Jun 25Form 4 |
| Jun 23, 2026 | Jennifer ChampouxCOO | Sale plan | 2,175 | $20.00 | $44K | 62,371 | Jun 25Form 4 |
| Jun 23, 2026 | Sharon TownsonChief Scientific Officer | Sale plan | 3,000 | $20.00 | $60K | 67,845 | Jun 25Form 4 |
| Jun 17, 2026 | Sharon TownsonChief Scientific Officer | Sale plan | 3,000 | $19.00 | $57K | 67,845 | Jun 18Form 4 |
| Jun 17, 2026 | Jennifer ChampouxCOO | Sale plan | 2,176 | $19.00 | $41K | 62,371 | Jun 18Form 4 |
| Jun 1, 2026 | Markus WarmuthPresident & CEO | Sale plan | 5,466 | $19.44 | $106K | 594,538 | Jun 2Form 4 |
| May 29, 2026 | Sharon TownsonChief Scientific Officer | Sale plan | 6,000 | $19.87 | $119K | 67,845 | Jun 1Form 4 |
| May 27, 2026 | Jennifer ChampouxCOO | Sale plan | 2,175 | $20.00 | $44K | 62,371 | May 28Form 4 |
GLUE insider trading FAQ
Are GLUE insiders buying or selling?
Insiders are only selling over the last 12 months. 0 insiders bought $0 of GLUE on the open market in 0 trades, and 8 sold $4.1M in 31 trades, 54% of that under pre-arranged trading plans.
When did an GLUE insider last buy shares?
Chandra P. Leo (Director) bought 10,000 shares for $58K on Mar 24, 2025, reported on Mar 25, 2025.
When did an GLUE insider last sell shares?
Matthew Bowen (Principal Accounting Officer) sold 13 shares for $137 on Oct 5, 2026.
What is a Form 4?
Company officers, directors and owners of more than 10% of the shares must report trades in the company's stock to the SEC on Form 4 within two business days. This page shows open market buys and sales only. Option exercises, stock awards, gifts and shares withheld for taxes are left out, since they are not decisions to buy or sell.
Why do insider sales matter less than buys?
Insiders sell for many reasons, such as taxes, diversification or a home purchase, and many sales are scheduled months ahead under a 10b5-1 trading plan. They buy on the open market mostly when they expect the shares to rise, which is why buying, and especially several insiders buying together, gets more attention.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Trades come from SEC Form 4 filings as reported by the insiders. Insiders have two business days to report, so a trade can be a few days old when it appears. See all insider cluster buys.
From SEC Form 4 filings · Not investment advice
